MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume $9.22 +0.58 (+6.71%) Closing price 04:00 PM EasternExtended Trading$9.02 -0.20 (-2.11%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MiNK Therapeutics Short Interest DataMiNK Therapeutics (INKT) has a short interest of 29,200 shares, representing 2.92% of the float (the number of shares available for trading by the public). This marks a 8.96% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 15,774 shares to cover all short positions.Current Short Interest29,200 sharesPrevious Short Interest26,800 sharesChange Vs. Previous Month+8.96%Dollar Volume Sold Short$247,908.00Short Interest Ratio0.9 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares3,966,000 sharesFloat Size1,000,000 sharesShort Percent of Float2.92%Today's Trading Volume5,870 sharesAverage Trading Volume15,774 sharesToday's Volume Vs. Average37% Short Selling MiNK Therapeutics? Sign up to receive the latest short interest report for MiNK Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartINKT Short Interest Over TimeINKT Days to Cover Over TimeINKT Percentage of Float Shorted Over Time Remove Ads MiNK Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202529,200 shares $247,908.00 +9.0%2.9%0.9 $8.49 2/28/202526,800 shares $239,860.00 -12.7%2.7%0.8 $8.95 2/15/202530,700 shares $291,650.00 +104.7%3.1%1 $9.50 1/31/202515,000 shares $137,400.00 -0.7%1.5%0.5 $9.16 1/15/202515,100 shares $131,354.90 -87.7%0.2%1.4 $8.70 12/31/2024123,000 shares $85,718.70 +160.6%1.2%1.3 $0.70 12/15/202447,200 shares $29,075.20 +9.8%0.5%1 $0.62 11/30/202443,000 shares $31,519.00 -15.2%0.4%1.1 $0.73 11/15/202450,700 shares $38,227.80 -1.9%0.5%1.4 $0.75 10/31/202451,700 shares $36,913.80 -20.8%0.5%1.5 $0.71 Get the Latest News and Ratings for INKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202465,300 shares $43,424.50 +34.4%0.7%1.7 $0.67 9/30/202448,600 shares $36,450.00 -21.6%0.5%0.8 $0.75 9/15/202462,000 shares $48,081.00 +22.5%0.6%1.2 $0.78 8/31/202450,600 shares $40,986.00 -21.3%0.5%0.9 $0.81 8/15/202464,300 shares $52,790.30 +5.1%1.1%1 $0.82 7/31/202461,200 shares $57,528.00 -27.9%1.2%0.4 $0.94 7/15/202484,900 shares $96,786.00 -10.3%1.6%0.6 $1.14 6/30/202494,600 shares $89,794.32 -19.6%1.8%0.6 $0.95 6/15/2024117,600 shares $108,156.72 -31.4%2.2%0.6 $0.92 5/31/2024171,300 shares $166,161.00 -66.9%3.2%0.9 $0.97 5/15/2024516,900 shares $537,576.00 +490.7%5.2%2.8 $1.04 4/30/202487,500 shares $86,625.00 +80.4%0.9%0.9 $0.99 4/15/202448,500 shares $44,062.25 +18.0%0.5%0.5 $0.91 3/31/202441,100 shares $37,331.13 -11.6%0.4%0.4 $0.91 3/15/202446,500 shares $41,594.25 +12.6%0.5%0.8 $0.89 2/29/202441,300 shares $38,049.69 -76.4%0.4%0.7 $0.92 2/15/2024175,100 shares $162,843.00 -7.6%1.8%3.4 $0.93 1/31/2024189,400 shares $163,831.00 +8.3%2.0%3.8 $0.87 1/15/2024174,900 shares $172,976.10 -1.7%1.8%3.8 $0.99 12/31/2023178,000 shares $190,460.00 +237.8%1.9%4.6 $1.07 12/15/202352,700 shares $53,754.00 -66.3%0.6%1.2 $1.02 11/30/2023156,400 shares $164,220.00 +2.4%1.6%3.9 $1.05 11/15/2023152,700 shares $155,754.00 -19.7%1.6%3.4 $1.02 10/31/2023190,100 shares $193,902.00 +11.7%2.0%3.6 $1.02 10/15/2023170,200 shares $187,220.00 +6.7%1.8%3 $1.10 9/30/2023159,500 shares $175,450.00 -11.7%1.8%2.4 $1.10 9/15/2023180,600 shares $232,974.00 -7.7%1.9%2.5 $1.29 8/31/2023195,700 shares $283,765.00 -1.0%2.1%1.9 $1.45 8/15/2023197,600 shares $337,896.00 -31.4%2.0%1.8 $1.71 7/31/2023288,000 shares $538,560.00 +6.9%3.0%2.1 $1.87Elon Tax Shock? (Ad)Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.Move now and you could get in first - with huge upside potential. 7/15/2023269,500 shares $493,185.00 +1.7%2.8%1.4 $1.83 6/30/2023264,900 shares $556,290.00 +68.5%2.7%1.4 $2.10 6/15/2023157,200 shares $377,280.00 +2.0%1.6%0.9 $2.40 5/31/2023154,100 shares $271,216.00 -14.6%1.7%1.2 $1.76 5/15/2023180,500 shares $305,045.00 +70.4%1.9%1.5 $1.69 4/30/2023105,900 shares $189,561.00 +117.5%1.1%1.1 $1.79 4/15/202348,700 shares $107,627.00 +34.2%1.1%2.8 $2.21 3/31/202336,300 shares $68,788.50 -14.0%0.8%3.2 $1.90 3/15/202342,200 shares $84,822.00 +92.7%1.0%3.6 $2.01 2/28/202321,900 shares $44,457.00 -60.9%0.5%2.2 $2.03 2/15/202356,000 shares $112,560.00 -19.4%1.3%4.6 $2.01 1/31/202369,500 shares $159,155.00 -10.6%1.6%3.2 $2.29 1/15/202377,700 shares $183,372.00 -15.2%1.7%3.4 $2.36 12/30/202291,600 shares $239,076.00 -7.0%2.0%3.9 $2.61 12/15/202298,500 shares $217,685.00 -34.9%2.1%4 $2.21 11/30/2022151,400 shares $401,210.00 -7.4%3.3%5.2 $2.65 11/15/2022163,500 shares $501,667.05 +24.0%3.5%4.6 $3.07 10/31/2022131,900 shares $287,542.00 +3.2%2.8%0.3 $2.18 10/15/2022127,800 shares $241,542.00 -0.8%2.8%0.3 $1.89 9/30/2022128,800 shares $271,768.00 +25.1%2.8%0.3 $2.11 9/15/2022103,000 shares $269,860.00 -46.1%2.2%0.2 $2.62 8/31/2022191,200 shares $502,856.00 +15.3%4.2%0.4 $2.63 8/15/2022165,800 shares $563,720.00 +400.9%3.7%0.4 $3.40 7/31/202233,100 shares $43,361.00 +0.3%0.8%0.8 $1.31 7/15/202233,000 shares $42,570.00 -35.6%0.8%0.8 $1.29 6/30/202251,200 shares $72,192.00 -57.2%1.2%0.9 $1.41 6/15/2022119,500 shares $223,465.00 -1.6%2.9%2 $1.87 5/31/2022121,400 shares $188,170.00 +33.6%2.9%2 $1.55 5/15/202290,900 shares $117,261.00 -16.0%2.2%1.4 $1.29 4/30/2022108,200 shares $242,368.00 -32.5%2.6%1.7 $2.24 4/15/2022160,400 shares $469,972.00 +5.0%3.8%2.2 $2.93 3/31/2022152,800 shares $343,800.00 -2.4%3.7%2 $2.25 3/15/2022156,500 shares $355,255.00 -7.6%3.8%1.9 $2.27 2/28/2022169,400 shares $503,118.00 +5.2%4.2%1.9 $2.97 2/15/2022161,000 shares $457,240.00 -21.8%4.0%1.7 $2.84 1/31/2022205,800 shares $677,082.00 -11.3%5.1%2.2 $3.29 1/15/2022231,900 shares $735,123.00 +139.1%N/A2.2 $3.17 12/31/202197,000 shares $432,620.00 No Change2.4%0.9 $4.46 INKT Short Interest - Frequently Asked Questions What is MiNK Therapeutics' current short interest? Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 29,200 shares of INKT short. 2.92% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest. What is a good short interest ratio for MiNK Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INKT shares currently have a short interest ratio of 1.0. Learn More on MiNK Therapeutics's short interest ratio. What is a good short interest percentage for MiNK Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.92% of MiNK Therapeutics' floating shares are currently sold short. Is MiNK Therapeutics' short interest increasing or decreasing? MiNK Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 29,200 shares, an increase of 9.0% from the previous total of 26,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MiNK Therapeutics' float size? MiNK Therapeutics currently has issued a total of 3,966,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 1,000,000 shares. How does MiNK Therapeutics' short interest compare to its competitors? 2.92% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to MiNK Therapeutics: Alector, Inc. (7.14%), Cassava Sciences, Inc. (27.14%), Lexeo Therapeutics, Inc. (8.90%), Telomir Pharmaceuticals, Inc. (11.30%), ProQR Therapeutics (1.36%), Genelux Co. (7.82%), Enanta Pharmaceuticals, Inc. (13.27%), Eupraxia Pharmaceuticals Inc. (0.55%), Instil Bio, Inc. (16.48%), Sagimet Biosciences Inc. (18.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short MiNK Therapeutics stock? Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. INKT shares are trading up $0.58 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MiNK Therapeutics? A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further. How often is MiNK Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies ALEC Short Interest SAVA Short Interest LXEO Short Interest TELO Short Interest PRQR Short Interest GNLX Short Interest ENTA Short Interest EPRX Short Interest TIL Short Interest SGMT Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INKT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INKT Stock Free INKT Stock Alerts